### **ORIGINAL RESEARCH**



Check for updates

# Minimal important difference in weight loss following bariatric surgery: Enhancing BODY-Q interpretability

Farima Dalaei <sup>1,2,3</sup> | Phillip J. Dijkhorst <sup>4</sup> | Sören Möller <sup>3,5</sup> |
Claire E. E. de Vries <sup>4,6</sup> | Lotte Poulsen <sup>1,2</sup> | Sophocles H. Voineskos <sup>7</sup> | Manraj N. Kaur <sup>6</sup> | Jørn Bo Thomsen <sup>1,2</sup> | Ruben N. van Veen <sup>8</sup> |
Claus B. Juhl <sup>9,10</sup> | Alin Andries <sup>10</sup> | René K. Støving <sup>11,12,13</sup> | Stefan J. Cano <sup>14</sup> | Anne F. Klassen <sup>15</sup> | Andrea L. Pusic <sup>6</sup> | Jens A. Sørensen <sup>1,2</sup> |

### Correspondence

Farima Dalaei, Research Unit of Plastic Surgery, Odense University Hospital, Denmark.

Email: farima.dalaei@gmail.com

### **Funding information**

Jascha Fonden, Grant/Award Number: 2021-0183; Region Syddanmark, Grant/Award Number: 21/17592; Odense Universitetshospital, Grant/Award Number: A5006

### **Summary**

BODY-Q is a patient-reported outcome measure for comprehensive assessment of outcomes specific to patients undergoing bariatric surgery. The clinical utility of BODY-Q is hampered by the lack of guidance on score interpretation. This study aimed to determine minimal important difference (MID) for assessment of BODY-Q. Prospective BODY-Q data from Denmark and the Netherlands pre- and post-bariatric surgery were collected. Two distribution-based methods were used to estimate MID by 0.2 standard deviations of baseline scores and the mean standardized response change of scores from baseline to 3-years postoperatively. In total, 5476 assessments from 2253 participants were included of which 1628 (72.3%) underwent Roux-en-Y

Farima Dalaei and Phillip J. Dijkhorst are co-first authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Author(s). Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

<sup>&</sup>lt;sup>1</sup>Research Unit of Plastic Surgery, Odense University Hospital, Odense, Denmark

<sup>&</sup>lt;sup>2</sup>Clinical Institute, University of Southern Denmark, Odense, Denmark

<sup>&</sup>lt;sup>3</sup>OPEN: Open Patient data Explorative Network, Odense, Denmark

<sup>&</sup>lt;sup>4</sup>Department of Surgery, OLVG West Hospital & Dutch Obesity Clinic (NOK), Amsterdam, The Netherlands

<sup>&</sup>lt;sup>5</sup>Odene University Hospital and University of Southern Denmark, Odense, Denmark

<sup>&</sup>lt;sup>6</sup>Department of Surgery, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA

<sup>&</sup>lt;sup>7</sup>Division of Plastic Surgery, Department of Surgery, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada

<sup>&</sup>lt;sup>8</sup>Department of Surgery, OLVG, Amsterdam, The Netherlands

<sup>&</sup>lt;sup>9</sup>Hospital of Southwest Jutland, Institute for Regional Health Research, University of Southern Denmark and Steno Diabetes Center, Odense, Denmark

<sup>&</sup>lt;sup>10</sup>Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Denmark

<sup>&</sup>lt;sup>11</sup>Center for Eating Disorders, Odense University Hospital, Odense, Denmark

<sup>&</sup>lt;sup>12</sup>Research Unit for Medical Endocrinology, Odense University Hospital, Odense, Denmark

<sup>&</sup>lt;sup>13</sup>Mental Health Services in the Region of Southern Denmark, Odense, Denmark

<sup>&</sup>lt;sup>14</sup>Modus Outcomes Ltd, Cheltenham, UK

<sup>&</sup>lt;sup>15</sup>Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada

7588111, 2024, 5, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/cob.12675, Wiley Online Library on [05/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Ceative Commons License

gastric bypass, 586 (26.0%) sleeve gastrectomy, 33 (1.5%) gastric banding, and 6 (0.03%) other surgeries. The mean age was 45.1 ± 10.9 with a mean BMI of 46.6 ± 9.6. Baseline MID ranged from 1 to 4 in health-related quality of life (HRQL) and from 2 to 8 in appearance scales. The mean change of scores ranged from 4 to 5 in HRQL and from 4 to 7 in the appearance scales. The estimated MID for the change in BODY-Q HRQL and appearance scales ranged from 3 to 8 and is recommended for use to interpret BODY-Q scores and assess treatment effects in bariatric surgery.

### KEYWORDS

bariatric surgery, BODY-Q, metabolic surgery, minimal important clinical difference, minimal important difference, patient-reported outcome measure, weight loss surgery

### What is already known about this subject

- For accurate assessment of the impact of bariatric surgery on patients' health-related quality of life, the use of reliable and valid condition-specific patient reported outcome measures (PROMs) is essential.
- · Among these measures, BODY-Q is recognized for having the strongest psychometric properties for use in patients undergoing medical and surgical weight management treatments.
- The minimal important difference (MID) for PROMs represents the smallest score change considered meaningful. MIDs are crucial for the interpretation and understanding of patients' scores

### What this study adds

- This study is the first to provide BODY-Q MID scores for patients undergoing bariatric surgery. This represents a significant advancement in PROM assessment.
- Previously, the clinical utility of BODY-Q was limited due to the lack of MID scores. This study addresses this gap, facilitating improved interpretation of scores and more effective evaluation of patient progress and the impact of bariatric surgery.
- By establishing MID scores, this study enhances the consistency in synthesizing patientreported outcomes. It allows clinicians to interpret patient results, monitor progress over time, and engage in more informed shared decision-making with patients more accurately.

### INTRODUCTION

Bariatric surgery is recognized as the most effective weight loss therapy for patients living with morbid obesity, resulting in long-term weight loss, remission of obesity-related conditions, and an improvement in health-related quality of life (HRQL). While the effectiveness of bariatric surgery has traditionally focused on weight loss only, it is currently evolving to encompass HRQL as a key outcome measure as well.<sup>2,3</sup> To measure the impact of bariatric surgery on patients' lives and HRQL, it is essential to use reliable and valid patient reported outcome measures (PROMs).<sup>4</sup> BODY-Q is a comprehensive PROM designed specifically to measure patient-reported outcomes (PRO) in patients undergoing bariatric surgery.<sup>5</sup> In recent systematic reviews, BODY-Q possessed the strongest measurement properties for patients seeking medical and surgical weight management treatment.<sup>6,7</sup>

Despite the benefits of BODY-Q, the clinical utility is hampered by the lack of guidance on score interpretation. There is a lack of the minimal important difference (MID) to evaluate patient progress and to demonstrate the magnitude of an intervention's effect, such as bariatric surgery. The MID is defined as the smallest change in score on the construct to be measured.<sup>8,9</sup> Without the MID, it can be difficult to determine whether an observed significant difference or change in BODY-Q scores are clinically meaningful or not, resulting in an inability to draw valid conclusions about the effectiveness of an intervention. 10

The methodology to estimate the MID can broadly be classified into distribution-based and anchor-based methods. Distribution-based methods estimate the MID based on the distribution of observed scores in a relevant sample, using the variability of scores either between patients (e.g., the standard deviation (SD) of patients at baseline) or within-patient variability (e.g., the SD of the change that patients experience during a study period). 11-13 When using a distribution-based method a reasonable effect size for discriminating change must be determined. Cohen has provided benchmarks for the interpretation of effect sizes: 0.2 for small effects, 0.5 for moderate effects, and 0.8 for large effects. <sup>14</sup> An effect size of 0.2 serve as an appropriate definition of a the MID based on a literature review of Samsa et al. 15 The anchor-based methods use an external, patientbased indicator, to compare the change in PRO score to the external anchor. <sup>16,17</sup> The anchor can be a single anchor (individual focused) or multiple anchors (population focused). <sup>11,18,19</sup> As anchor-based methods are patient-centred approaches, they are considered superior to distribution-based methods that rely solely on the statistical properties of a sample. <sup>20</sup> However, the variety and subjectivity of possible anchors, combined with the uncertainty in defining the MID anchor cut point, make determining a single MID estimate challenging. <sup>10</sup> Concurrently, the distribution-based methods offer an easily accessible insight into measurement variability and serve as a starting point for establishing the MID. <sup>21</sup>

The growing interest in measuring PRO in bariatric surgery emphasizes the need of the BODY-Q to be able to detect meaningful changes in patents' lives. 2,3,22 Estimating the MID is crucial to enhance the interpretability of the change in scores of the BODY-Q. The aim of this study was to establish a MID starting point for the BODY-Q in a multinational cohort of patients undergoing bariatric surgery using the distribution-based methods. The MID is essential for accurate assessment of the impact of bariatric surgery on patients' HRQL to provide applicable and valuable information for healthcare professionals, research investigators, and decision-makers. 23,24

### 2 | METHODS

Data for this study was extracted from a multicentre, international prospective cohort study investigating change in HRQL and appearance throughout the weight loss trajectory from pre-bariatric surgery to post-bariatric body contouring surgery. The cohort is registered in ClinicalTrials.gov (https://clinicaltrials.gov) with the following identification number: NCT05272215. Only patients undergoing bariatric surgery were included in this study to provide bariatric-specific MIDs. The study was conducted according to the Declaration of Helsinki principles and was approved by the local ethics committee from the respective site prior to study commencement.

### 2.1 | Study population

The cohort was recruited from the following countries and hospitals: Denmark (Department of Endocrinology, Odense University Hospital, Odense and Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg) and the Netherlands (OLVG West Hospital, Amsterdam, and St. Antonius Hospital, Nieuwegein). Patients aged 18 years or older who visited one of five hospitals were invited to participate in the study. Patients with insufficient proficiency in the Danish or in Dutch language or with cognitive impairments were excluded.

### 2.2 | Questionnaire administration

Data were collected at baseline (preoperatively) and postoperatively at the following timepoints: 3–6 months, 1 year, 2 years, and 3 years.

In Denmark, patients were recruited between June 2015 and November 2021. Patients received a direct link to the questionnaire through either the Research Electronic Data Capture (REDCap), Open Patient data Explorative Network (OPEN), or Odense University Hospital, through patient's secure electronic mailbox. Patients were also offered the chance to fill out the questionnaire at their hospital appointments in the clinic using an iPad. In the Netherlands, patient was recruited between October 2018 and October 2019. Participants were recruited via a URL link directly in Castor EDC. Patients were encouraged to complete the entire questionnaire. However, as the individual scales making up the BODY-Q function independently, partially completed assessments were also included. Besides the BODY-Q scales, patients were asked to provide the following characteristics: age, gender, weight, height, marital status, educational level, comorbidities prior to bariatric surgery, and type of bariatric surgery. The inclusion period for the two countries differed as the BODY-Q was translated and validated in Denmark and the Netherlands at different times. 25,26 Specifically, the Danish BODY-O database was established in 2015. Subsequently, the Dutch Obesity Clinic began its data collection for the BODY-O. Data from the Netherlands was transferred to Denmark in 2019 in accordance with our data transfer agreement.

### 2.3 Outcome measure: The BODY-Q

BODY-Q was developed using Rasch Measurement Theory and details regarding the development and validation have previously been published.<sup>5</sup> In brief, BODY-Q consists of four domains, HRQL, appearance, eating-related concerns, and experience of care.<sup>27</sup> The BODY-Q scales were translated into the given language of each country in accordance with recommended guidelines of the International Society for Pharmacoeconomics and Outcomes Research and the World Health Organization.<sup>24,26,28</sup> In this study, the following scales were included: HRQL (psychological, physical function, body image, sexual, and social) and appearance (body, abdomen, arms, back, buttocks, hips and outer thighs, inner thighs, chest, nipples, stretchmarks, and skin).

Each scale of BODY-Q has between four and 10 items, scored on a Likert scale from 1 (i.e., very dissatisfied) to 4 (i.e., very satisfied). The summed raw scores of all items in a scale are transformed using Rasch Conversion Tables to generate a score between 0 and 100. A score of 0 indicates the worst outcome, while 100 indicates the best outcome. There is no total score of the BODY-Q as each scale is scored independently.<sup>5</sup>

### 3 | STATISTICAL ANALYSIS AND DETERMINATION OF MID

Descriptive statistics including mean, standard deviation, and 95% confidence interval (95% CI) for patient characteristics were computed for continuous variables, and percentages were computed for

categorical variables. The summed raw BODY-Q scores for each scale, were transformed to Rasch converted scores (from 0 to 100). For all scales, the median and interquartile range (IQR: 25th percentile, and 75th percentile) of the patients' scores were used to generate a score interpretation tool.

To determine the MID for the BODY-Q scales, two distribution-based analyses were performed. First, the sample baseline standard deviation (SD) was used as a measure of the sample variation. In this approach, we choose a conservative threshold to discriminate change, hence one one-fifth of the SD was used as a distribution-based threshold.<sup>15</sup>

The 0.2 SD of preoperative (baseline) BODY-Q scores were determined. The percentage of patients achieving the estimated MID at each timepoint from baseline to 3 years postoperatively was calculated. This method and effect size have previously been used in the BREAST-Q Reconstruction module and for Breast-Conserving Therapy.<sup>29,30</sup> Second, 0.2 of the standardized response change of mean (SRM) from baseline to each postoperative timepoint was used to calculate the change MID. In addition, the MID was also estimated based on Body Mass Index (BMI) groups (BMI <18.49, 18.5-24.9, 25.0-29.9, 30-34.9, 35-39.9, >40 kg/m<sup>2</sup>), gender (male and female), and age groups (18-29, 30-39, 40-49, 50-59, >60 years) to evaluate if a separate MID would increase the interpretability of the scores based on stratification of patient characteristics. We used a mixed-effects linear regression model to investigate the impact of patient covariates including age, gender, and BMI on each scale. All data analyses were performed using StataBE Version 17 (College Station, TX, California, United States).

### 4 | RESULTS

### 4.1 | Baseline characteristics

In total, the sample consisted of 5476 assessments from 2253 patients of which 73.8% underwent laparoscopic Roux-en-Y gastric bypass (LRYGB), 24.4% underwent laparoscopic sleeve gastrectomy (LSG), 1.4% underwent gastric banding, and 0.1% underwent other surgeries. Participant demographics and characteristics are presented in Table 1. The follow-up period ranged from pre-bariatric surgery to 3 years postoperatively. The cohort consisted of 76% females and 24% males, with a mean age of  $45.1 \pm 10.9$  years and a mean baseline BMI of  $45.2 \pm 7.5$  kg/m<sup>2</sup>. Three-years postoperatively, the patients had a mean BMI of  $30.4 \pm 7.3$  kg/m<sup>2</sup>.

### 4.2 | Minimal important difference

Baseline 0.2 SD derived BODY-Q MID scores are presented in Table 2. On the Rasch transformed (0–100) scale, the MID estimate was between 1 and 4 in the HRQL domain and between 2 and 8 in the appearance domain. The MID estimates based on 0.2 SRM from baseline to 3 years postoperatively for the HRQL- and appearance

domains are presented in Table 3. The MID estimates for the change from baseline to 6 months, 1-, 2-, and 3-years were between 4 and 7.

### 4.3 | Proportion of patients with clinically meaningful improvement

Figure 1 shows the median, 25th percentile and 75th percentile BODY-Q scores for each HRQL and appearance scale from baseline to 3 years after bariatric surgery. Additionally, the percentage of patients who achieved MID at each timepoint are presented. In all the scales, the BODY-Q scores improved and stabilized after surgery except for the skin, chest, and nipple scales, where the median was unchanged after surgery and slightly lower 2 years post-bariatric surgery compared to baseline values. See supplementary for the total number of patients in each scale and percentage of patients who achieved the estimated MID (Supplementary 1).

### 4.4 | BMI stratified minimal important difference

The 0.2 SD from baseline MIDs were stratified in age, BMI, and gender groups presented in Table 4. In all scales, older age was associated with a higher MID score. Overall, there were no differences between male and female participants.

### 5 | DISCUSSION

In this study, BODY-Q MID estimates were determined for patients undergoing bariatric surgery based on two distribution-based methods. The MID based on SRM from baseline to 3 years postoperatively was between 4 and 5 for HRQL scales and 4 and 7 for the appearance scales, while the baseline MID estimates were between 1 and 4 for HRQL scales and 2 and 8 for appearance scales. Stratifying the MID by BMI and gender showed no overall differences. However, higher age was associated with higher MID scores. To the best of our knowledge, this is the first effort to establish MID for the BODY-Q in a bariatric cohort. Patients, physicians, and research investigators can compare their results with these MID reference values over time, to identify patients who may benefit from potential interventions.

The use of the SRM instead of baseline SD for determining the MID offers a distinct benefit as it includes the variability in change, and thus, does not rely on the baseline heterogeneity of the sample. 

18,29,30 Therefore, we currently recommend the use of the mean MID derived from the SRM from baseline to 3 years postoperatively shown in Table 3 for research and clinical use. This study contributes with a conservative starting estimate for the MID with the use of a Cohens' small effect size of 0.2 as used in the BREAST-Q MID studies. 

29,30 Figure 1 shows that most patients achieved the MID estimates determined from 0.2 SRM with HRQL ranging from 59% (sexual) to 93% (body image) and the appearance scales from 29% (skin) to 96% (body). In all scales, BODY-Q scores improved and

ABLE 1 Participant	characteristics.		
Characteristics	Total	Netherlands	Denmark
Patients n (%)	2253	697 (30.1)	1556 (69.1)
Assessments n (%)	10 355	7088 (68.5)	3267 (31.5)
Gender n (%)	2253	697	1556
Female	1711 (75.9)	571 (81.9)	1140 (73.3)
Male	542 (24.1)	126 (18.1)	416 (26.7)
Other	0 (0)	0 (0)	0 (0)
Age	2139	583	1556
Mean (SD)	45.1 (10.9)	44.6 (11.4)	45.6 (10.3)
Minimum: Maximum	18.0; 78.2	18.0; 68.1	21.3; 78.2
Age group	2139	583	1556
17-29	227 (10.6)	90 (15.4)	137 (8.8)
30-39	513 (24.0)	114 (19.6)	399 (25.6)
40-49	652 (30.5)	172 (29.5)	480 (30.8)
50-59	587 (27.4)	168 (28.8)	419 (26.9)
>60	160 (7.5)	39 (6.7)	121 (7.8)
Missing	114	114 (19.5)	0
BMI (baseline)	2075	583	1492
Mean (SD)	46.6 (9.61)	43.9 (7.91)	49.3 (11.23)
Minimum: Maximum	30.1; 79.7	30.8; 67.9	30.1; 79.7
BMI groups	2075	583	1492
<18.49	0 (0)	0 (0)	0 (0)
18.5-24.9	1 (0.04)	1 (0.1)	0 (0)
25-29.9	10 (0.5)	3 (0.5)	7 (0.5)
30-34.9	30 (1.4)	9 (1.5)	21 (1.4)
35-39.9	351 (16.9)	135 (23.2)	216 (14.5)
>40	1683 (81.1)	435 (74.6)	1248 (83.6)
Missing	178	114	64
Comorbidities n (%)	2253	697	1556
Diabetes	266 (11.8)	86 (12.3)	180 (11.6)
Hypertension	350 (15.5)	174 (25.0)	176 (11.3)
Hyperlipidaemia	117 (5.1)	75 (10.8)	42 (2.7)
Obstructive sleep apnoea	294 (13.0)	204 (29.3)	90 (5.8)
Osteoarthritic disease	253 (11.2)	109 (15.6)	144 (9.3)
Cardiovascular or coagulation disease	101 (4.5)	69 (9.9)	32 (2.1)
Psychiatric	141 (6.3)	141 (20.2)	-
Reflux disease	223 (9.9)	223 (32.0)	-
No medical condition	994 (4.4)	213 (30.6)	781 (50.2)
Missing	0	0	0
Educational level n (%)	2109	558	1551
Elementary	54 (2.6)	21 (3.8)	33 (2.1)
Attending high school	350 (16.6)	78 (14.0)	272 (17.5)
High school diploma	510 (24.2)	238 (42.7)	473 (30.5)
Some college-, trade-, or university degree	336 (15.9)	148 (26.5)	324 (20.9)
Linivaraitus baabalaria	(27 (20 7)	27 (4 4)	200 (25.4)

University bachelor's

degree

627 (29.7)

37 (6.6)

TABLE 1 (Continued)

TABLE 1 (Continued)			
Characteristics	Total	Netherlands	Denmark
University master's degree	201 (9.5)	12 (2.2)	53 (3.4)
Doctoral degree	31 (1.5)	24 (4.3)	7 (0.4)
Missing	144	139	5
Marital status n (%)	2109	559	1550
Married	976 (46.3)	271 (48.5)	705 (45.5)
Living common law/relationship	501 (23.8)	127 (22.7)	374 (24.1)
Widowed	17 (0.8)	8 (1.4)	9 (0.6)
Separated/divorced	217 (10.3)	60 (10.7)	157 (10.1)
Single	398 (18.9)	93 (16.6)	305 (19.7)
Missing	145	139	6
Type of weight loss surgery	2253	697	1556
LRYGB (gastric bypass)	1628 (72.3)	430 (61.7)	1.198 (77.0)
LSG (gastric sleeve)	586 (26.0)	249 (35.7)	337 (21.7)
Gastric banding	33 (1.5)	14 (2.0)	19 (1.2)
Other	6 (0.03)	4 (0.06)	2 (0.01)

Abbreviations: %, indicates the proportion of patients; *n*, number of patients; SD, standard deviation.

TABLE 2 Baseline minimal important differences.

	Appear	ance		
Scales	N	SD	0.2 SD	MID estimate 0.2
Body	2065	12.85	2.57	3
Abdomen	2090	10.36	2.07	2
Back	2067	23.54	4.71	5
Buttocks	2058	23.00	4.60	5
Arms	2073	22.87	4.57	5
Inner thighs	2052	20.89	4.18	4
Hips and outer thighs	2044	22.76	4.55	5
Chest	415	17.98	3.60	4
Nipples	409	28.80	5.76	6
Stretch marks	1723	28.07	5.61	6
Skin	1031	38.67	7.73	8
	Health-	related qu	uality of life	e

	Health-	related q	uality of life	e
Scales	N	SD	0.2 SD	MID estimate 0.2
Psychological	1684	6.40	1.28	1
Social	1684	5.47	1.09	1
Sexual	1656	5.42	1.08	1
Physical	1679	9.22	1.84	2
Body image	1683	6.23	1.25	1

Abbreviations: MID, minimal important difference; N, number of patients; SD, standard deviation.

(Continues)

389 (25.1)

TABLE 3 Standardized response mean.

RODY-O	Psy	Psychological			Social				Sexual				Physical	ca			Body image	mage		
Timepoint after BS	z	0.2 SRM	MID estimate	te	z	0.2 SRM	MID estimate	nate	z	0.2 SRM	MID estimate	lte	z	0.2 SRM	MID estimate	ate	z	0.2 SRM	MID	MID
6 months	440	4.25	4		438	3.64	4		411	4.29	2		439	5.00	2		438	4.50	2	
1-Year post-BS	457	4.92	2		456	3.90	4		427	4.79	2		455	5.52	9		456	4.91	2	
2-Years post-BS	375	4.67	2		376	4.00	4		346	5.01	2		374	5.28	2		375	5.29	2	
3-Years post-BS	92	4.78	2		91	4.09	4		72	4.48	2		93	5.13	2		94	5.55	9	
Mean			2				4				2				2				2	
BODY-Q Body	φ		Abdomen	e		Back			Buttocks	ks		Arms			Inner thighs	highs		Hips	Hips and outer thighs	thighs
Timepoint N	0.2 SRM	MID estimate	z	0.2 I SRM	MID	z	0.2 SRM	MID	z	0.2 SRM	MID	z	0.2 SRM	MID	z	0.2 SRM	MID	z	0.2 SRM	MID
6 months 454 post-BS	4 4.30	4	468	4.80	25	459	5.86	9	450	5.19	22	465	4.47	2	446	5.02	25	450	5.72	9
1-Year 486 post-BS	6 4.30	4	493	4.88	22	484	5.95	9	478	5.55	9	486	4.34	4	475	5.03	25	472	5.89	9
2-Years 400 post-BS	0 4.41	4	412	5.56	9	400	6.16	9	395	5.80	9	409	4.27	4	393	5.54	9	394	5.93	9
3-Years 100 post-BS	0 4.98	22	109	6.07	9	104	5.75	9	86	5.94	9	106	4.76	2	64	5.29	25	95	6.35	9
Mean		4			9			9			9			5			2			9
BODY-Q BS	Z	Nipples				Chest	<b>.</b>				Stretc	Stretch Marks				Skin	_			
Timepoint	Z	0.2 SRM	RM.	MID estimate	timate	z	0.2	0.2 SRM	MID estimate	timate	z	0.2	0.2 SRM	MID estimate	timate	z	0.	0.2 SRM	MID	MID estimate
6 months post-BS	S 71	1 5.34		2		73	4.43	<b>~</b>	4		365	5.18	8	5		274		6.75	7	
1-Year post-BS	7	79 5.14		2		80	4.77		2		386	4.95	2	2		263		5.83	9	
2-Years post-BS		65 5.22		2		9	4.66	.0	2		312	5.32	2	2		240		6.25	9	
3-Years post-BS	1	12 5.14		2		12	4.67		2		29	6.18	8	9		77		7.78	8	
Mean				2					5					2					7	

Abbreviations: MID, minimal important difference; N, number of patients; post-BS, post bariatric surgery; SRM, standardized response mean.

17588111, 2024, 5, Downloaded from https://onlinelbtrary.wiley.com/doi/10.1111/cob.12675, Wiley Online Library on [05/08/2025], See the Terms and Conditions (https://onlinelbtrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons Licenses




FIGURE 1 BODY-Q scores from baseline to 3 years after bariatric surgery.

 TABLE 4
 Gender, age, and BMI stratified minimal important differences.

		-		Aldenses		V		-		1		<u>:</u>		1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		Charles Mande		.!	
		Boay		Abdome	_	ALIIIS		Dack		Buttocks		8     S		Inigns		Stretch	viarks	   X 	
		z	MID	z	MD	z	ΔID	z	ΔID	z	MID	z	₫	z	MID	z	M	z	ΔM
Age	17-29	136	2	136	1	135	က	135	က	135	4	136	4	136	2	135	2	39	9
	30-39	396	2	396	2	394	4	395	4	396	4	396	4	395	ო	395	2	131	4
	40-49	478	ဗ	475	2	476	2	474	4	475	2	474	2	474	4	439	2	168	2
	50-59	413	2	412	2	411	2	411	4	411	2	411	2	411	4	342	9	144	4
	09^	121	က	121	2	121	2	120	2	120	2	121	2	119	2	78	2	35	4
BMI	<18.5	0	ı	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	ı
	18.5-24.9	0	ı	0	ı	0	ı	0	ı	0	ı	0	1	0	ı	0	ı	0	ı
	25-29.9	9	1	9	1	9	1	9	2	9	1	9	1	9	1	9	0.2	9	2
	30-34.9	21	1	21	1	21	1	21	2	21	2	21	1	21	0.5	19	1	10	4
	35-39.9	214	2	213	1	213	1	212	2	213	2	213	ო	212	2	177	2	82	2
	>40	1241	1	1239	1	1236	1	1233	2	1236	1	1237	7	1234	2	1132	1	402	4
Gender	Female	1571	ო	1591	2	1577	4	1574	4	1566	4	1555	4	1562	ო	1347	9	863	8
	Male	494	က	499	2	496	2	493	2	492	2	489	2	490	2	376	9	168	8
			Psyc	Psychological			Physical			Sexual	<u>-</u>			Social			Body Image	nage	
			z		₽		z	Σ	<u>Q</u>	z		₽		z	MID	۱۵	z		MB
Age	17-29		135	5	4		135	4		133		4		135	ო		135		က
	30-39		395	5	4		395	4		388		4		395	4		393		က
	40-49		470	0	4		470	4		470		2		472	4		472		က
	50-59		410	0	4		409	4		403		2		411	4		410		က
	09<		121	1	4		121	9		120		2		121	4		120		က
BMI	<18.5			0	1		0	1		0		ı		0	1		0		ı
	18.5-24.9	4.9		0	ı		0	1		0		ı		0	ı		0		ı
	25-29.9	6.		9	1		9	1		9		1		9	ო		9		က
	30-34.9	6.	21	1	2		21	က		21		7		21	1		21		1
	35-39.9	6.	212	2	2		208	က		210		1		212	2		213		1
	>40		1232	2	7		1230	7		1217		1		1234	1		1230		1
Gender	Female		1553	က	4		1549	4		1515		2		1544	4		1549		က
	Male		485	2	4		485	4		469		2		486	4		484		က
Abbreviation	Abbreviations: BMI hody mass index: MID minimal important difference:	se index.	VID minin	nal import;	ant differe	N DIII	N number of patients	ients											

Abbreviations: BMI, body mass index; MID, minimal important difference; N, number of patients.

stabilized after surgery except for the skin scale, where the score median was unchanged after surgery, and in fact slightly lower 2 years after surgery compared to baseline values. This might be due to the fact that most of these patients did not undergo post-bariatric body contouring surgery at the time of measurement. In a recent up to 10-year longitudinal follow-up, our team showed, that patients who did not undergo body contouring after bariatric surgery reported lower HRQL and satisfaction with appearance. <sup>31</sup>

Previous studies investigating the effect of bariatric surgery on HRQL, and appearance showed improvement after bariatric surgery across various scales of the BODY-Q. The clinical relevance of these effect sizes, however, were limited by the inability to compare the change in scores with reference values. 3,32-34 Consequently, the BODY-Q normative scores were determined to facilitate the comparison of patients undergoing bariatric surgery and reference values derived from the general population. 35,36 However, despite this development, the magnitude of a clinically relevant change in BODY-Q scores for patients undergoing bariatric surgery remained unknown. Together with the BODY-Q normative reference values, the MID reported in this paper can enhance the interpretability of the BODY-Q by providing a context for understanding the meaning and significance of changes in the scores.<sup>37</sup> For clinicians, the MIDs can be used to better understand patient's perception of HRQL and satisfaction with appearance, monitor patient progress over time, and evaluate the impact and efficacy of different treatments.<sup>20</sup> Overall, the use of MIDs to interpret scores can aid in shared decision-making and improve patient care. Additionally, research investigators can use the MIDs in future studies to guide the calculation of sample size and help interpret results.29

This study only generates the MID for patients undergoing bariatric surgery. The strengths of this study include the use of a reliable, psychometrically validated, and responsive condition-specific PROM in a large multinational cohort for the MID estimation of the BODY-Q scales. The large sample size of 2253 patients should not influence the magnitude of the MID, as it is expressed as an average variation around a mean value. Furthermore, we accounted for the potential different clinical characteristics (BMI, gender, age) by performing subgroup analyses, and verified that BMI and gender did not impact the MID estimates, only higher age was associated with higher MID estimates.

The study had some limitations that must be acknowledged. First, the use of a distribution-based method to estimate the MID, solely based on statistical measures, may not capture the clinical significance of the change in PRO.<sup>24</sup> The U.S. Food and Drug Administration (FDA) recent guidance recommend the use of either the anchor-based method or a combination of multiple methods, as the change in HRQL is linked to a meaningful external anchor, and hence incorporates the patient's perspective.<sup>24</sup> However, one of the limitations of anchorbased methods are the selection of appropriate anchors, as the subjective choice of individual patients may not be generalizable.<sup>20</sup> The distribution-based method has been criticized by the use of sample variability that may differ from study to study, and therefore not necessarily reflect the patient's perspective.<sup>20,24</sup> Due to this limitation,

the 0.2 SRM was estimated and recommended, which is not dependent on the sample's baseline heterogeneity. Furthermore, the results of three centres located in two different countries were combined in this study to increase the generalizability of the minimal important estimates.

In future, a combined distribution-based and anchor-based method should be applied due to the limitations of each method, hence we acknowledge that future studies may demonstrate different MID values.<sup>20</sup> However, until the minimally important values obtained through the anchor-based method become available, the estimates presented in this study is recommended for use.

### 6 | CONCLUSION

The estimated BODY-Q MID scores from baseline to 3 years postoperatively ranged between 3 and 5 for the HRQL and between 4 and 8 for the appearance domain. These clinical reference values provide valuable information for the interpretation of BODY-Q scores in future studies, improving the utility of this PROM as a tool for clinical research and patient care. Further studies should be performed using a combined distribution-based and anchor-based method to compare with the estimates in this study.

#### **ACKNOWLEDGEMENTS**

The authors are very thankful to all the participants for their contribution by completing the BODY-Q questionnaires.

### **FUNDING INFORMATION**

This study was supported by following research grants: Odense University Hospital (A5006), the Region of Southern Denmark (21/17592), and the Jascha Fund (2021-0183).

### **CONFLICT OF INTEREST STATEMENT**

The BODY-Q is co-developed by Stefan Cano, Anne F. Klassen, and Andrea L. Pusic, and they all receive a share of any licence revenues based on their institutions inventor sharing policy. Stefan Cano is CSO of Modus Outcomes, a Division of Thread. Anne F. Klassen is the owner of EVENTUM Research which provides consulting services to the pharmaceutical industry. The remaining authors declare no conflicts of interest.

### **ORCID**

Farima Dalaei https://orcid.org/0000-0003-2305-7758

Phillip J. Dijkhorst https://orcid.org/0000-0003-2913-8559

Claire E. E. de Vries https://orcid.org/0000-0001-8885-9546

Lotte Poulsen https://orcid.org/0000-0003-4205-806X

Sophocles H. Voineskos https://orcid.org/0000-0003-3818-2164


Manraj N. Kaur https://orcid.org/0000-0002-1911-0395

Jørn Bo Thomsen https://orcid.org/0000-0002-7368-6133

Claus B. Juhl https://orcid.org/0000-0002-4285-5459

René K. Støving https://orcid.org/0000-0002-4255-5544

Stefan J. Cano https://orcid.org/0000-0001-9390-273X



Anne F. Klassen https://orcid.org/0000-0003-4720-0096

Andrea L. Pusic https://orcid.org/0000-0003-4352-9409

Jens A. Sørensen https://orcid.org/0000-0003-4903-0094

### **REFERENCES**

- Shoar S, Mahmoudzadeh H, Naderan M, et al. Long-term outcome of bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis of 950 patients with a minimum of 3 years followup. Obes Surg. 2017;27(12):3110-3117.
- Mou D, DeVries CEE, Pater N, et al. BODY-Q patient-reported outcomes measure (PROM) to assess sleeve gastrectomy vs. Roux-en-Y gastric bypass: eating behavior, eating-related distress, and eatingrelated symptoms. Surg Endosc. 2021;35(8):4609-4617.
- Makarawung DJS, de Vries CEE, List EB, et al. Patient-level factors associated with health-related quality of life and satisfaction with body after bariatric surgery: a multicenter, cross-sectional study. Obes Surg. 2022;32(9):3079-3087.
- de Vries CEE, Terwee CB, Al Nawas M, et al. Outcomes of the first global multidisciplinary consensus meeting including persons living with obesity to standardize patient-reported outcome measurement in obesity treatment research. *Obes Rev.* 2022;23:e13452.
- Klassen AF, Cano SJ, Alderman A, et al. The BODY-Q: a patientreported outcome instrument for weight loss and body contouring treatments. Plast Reconstr Surg Glob Open. 2016;4(4):e679.
- de Vries CEE, Kalff MC, Prinsen CAC, et al. Recommendations on the most suitable quality-of-life measurement instruments for bariatric and body contouring surgery: a systematic review. *Obes Rev.* 2018; 19(10):1395-1411.
- Barone M, Cogliandro A, Salzillo R, Tambone V, Persichetti P. Patientreported satisfaction following post-bariatric surgery: a systematic review. Aesthetic Plast Surg. 2018;42(5):1320-1330.
- Warkentin LM, Majumdar SR, Johnson JA, et al. Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: two-year prospective cohort study. BMC Med. 2014;12:175.
- McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. *Jama*. 2014;312(13):1342-1343.
- Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102-109.
- Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. *Mayo Clin Proc.* 2002;77(4):371-383.
- Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215-1219.
- Voineskos SH, Nelson JA, Klassen AF, Pusic AL. Measuring patientreported outcomes: key metrics in reconstructive surgery. *Annu Rev Med*. 2018;69:467-479.
- Cohen J. Statistical Power Analysis for the Behavioral Science. 2nd ed. Academic Press; 1988.
- Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. *Pharmacoeconomics*. 1999:15(2):141-155.
- Terwee CB, Peipert JD, Chapman R, et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021;30(10):2729-2754.
- 17. de Vet HC, Terluin B, Knol DL, et al. Three ways to quantify uncertainty in individually applied "minimally important change" values. *J Clin Epidemiol*. 2010;63(1):37-45.
- Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395-407.

- Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res. 2005;14(2):285-295.
- Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898-910.
- Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making. Guidance for Industry, Food and Drug Administration (FDA) Staff, and Other Stakeholders. April 2023; pp. 1–41. Accessed July 25, 2023. https:// www.fda.gov/media/166830/download
- Dijkhorst PJ, Makarawung DJS, Vanhommerig JW, et al. Predictors of improved psychological function after bariatric surgery. Surg Obes Relat Dis. 2023;19:872-881.
- Brozek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes. 2006;4:69.
- 24. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Guidance for Industry, FDA. 2009. Accessed May 4, 2023. https://www.fda.gov/ regulatory-information/search-fda-guidance-documents/patientreported-outcome-measures-use-medical-product-developmentsupport-labeling-claims
- Poulsen L, Klassen A, Rose M, et al. Psychometric validation of the BODY-Q in Danish patients undergoing weight loss and body contouring surgery. *Plast Reconstr Surg Glob Open*. 2017;5(10): e1529.
- 26. de Vries CEE, Tsangaris E, Makarawung DJS, et al. Validation of the Dutch version of the BODY-Q measuring appearance, health-related quality of life, and experience of healthcare in patients undergoing bariatric and body contouring surgery. Aesthet Surg J. 2023;43(5): 569-579.
- Klassen AF, Cano SJ, Kaur M, Breitkopf T, Pusic AL. Further psychometric validation of the BODY-Q: ability to detect change following bariatric surgery weight gain and loss. *Health Qual Life Outcomes*. 2017;15(1):227.
- Poulsen L, Rose M, Klassen A, Roessler KK, Sørensen JA. Danish translation and linguistic validation of the BODY-Q: a description of the process. Eur J Plast Surg. 2017;40(1):29-38.
- Chu JJ, Tadros AB, Gallo L, et al. Interpreting the BREAST-Q for breast-conserving therapy: minimal important differences and clinical reference values. Ann Surg Oncol. 2023;30(7):4075-4084.
- Voineskos SH, Klassen AF, Cano SJ, Pusic AL, Gibbons CJ. Giving meaning to differences in BREAST-Q scores: minimal important difference for breast reconstruction patients. *Plast Reconstr Surg.* 2020; 145(1):11e-20e.
- Dalaei F, de Vries CEE, Poulsen L, et al. Body contouring surgery after bariatric surgery improves long-term health-related quality of life and satisfaction with appearance: an international longitudinal cohort study using the BODY-Q. Ann Surg. 2024;279:1008-1017.
- Elfanagely O, Rios-Diaz AJ, Cunning JR, et al. A prospective, matched comparison of health-related quality of life in bariatric patients following truncal body contouring. *Plast Reconstr Surg.* 2022;149(6): 1338-1347.
- Elfanagely O, Othman S, Mellia JA, Messa CA, Fischer JP. Quality of life and complications in the morbidly obese patient following postbariatric body contouring. Aesthetic Plast Surg. 2021;45(3):1105-1112.
- 34. Uimonen M, Repo JP, Homsy P, et al. Health-related quality of life in patients having undergone abdominoplasty after massive weight loss. *J Plast Reconstr Aesthet Surg.* 2021;74(9):2296-2302.

- 35. Dalaei F, de Vries CEE, Poulsen L, et al. General population normative scores for interpreting the BODY-Q. *Clin Obes.* 2022;12:e12528.
- Dalaei F, de Vries CEE, Cano SJ, et al. BODY-Q normative scores: psychometric validation of the BODY-Q in the general population in Europe and North America. Plast Reconstr Surg Glob Open. 2023;11(11):e5401.
- Devji T, Carrasco-Labra A, Qasim A, et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ. 2020;369:m1714.
- 38. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. *J Clin Epidemiol*. 2004;57(11):1153-1160.

### SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Dalaei F, Dijkhorst PJ, Möller S, et al. Minimal important difference in weight loss following bariatric surgery: Enhancing BODY-Q interpretability. *Clinical Obesity*. 2024;14(5):e12675. doi:10.1111/cob.12675

## Minimal important difference in weight loss following bariatric surgery: Enhancing BODY-Q interpretability

### **Authors (\*co-first authors):**

- 1. \*Farima Dalaei (MD), Research Unit of Plastic Surgery, Odense University Hospital, Denmark; Clinical Institute, University of Southern Denmark, Odense Denmark; OPEN: Open Patient data Explorative Network, Odense, Denmark. <a href="mailto:Farima.dalaei@gmail.com">Farima.dalaei@gmail.com</a>
- 2. \*Phillip J. Dijkhorst (MD), Department of Surgery OLVG West Hospital & Dutch Obesity Clinic (NOK), Amsterdam, the Netherlands. <a href="mailto:phillip.dijkhorst@gmail.com">phillip.dijkhorst@gmail.com</a>.
- 3. Sören Möller (MSc PhD), OPEN: Odense Patient data Explorative Network, Odense, University Hospital and University of Southern Denmark, Odense, Denmark. <a href="mailto:Soren.moller@rsyd.dk">Soren.moller@rsyd.dk</a>
- 4. Claire E. E. de Vries (MD, PhD), Department of Surgery, OLVG West Hospital, Amsterdam, Netherlands. Department of Surgery. Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, United States. <a href="mailto:Devries.cee@gmail.com">Devries.cee@gmail.com</a>
- 5. Lotte Poulsen (MD, PhD), Research Unit of Plastic Surgery, Odense University Hospital, Denmark; Clinical Institute, University of Southern Denmark, Odense Denmark. lotte poulsen@hotmail.com.
- 6. Sophocles H. Voineskos (MD, MSc, Associate Professor), Division of Plastic Surgery,
  Department of Surgery, Li Ka Shing Knowledge Institute, University of Toronto, Toronto,
  Ontario, Canada. <a href="mailto:Sophocles.voineskos@medportal.ca">Sophocles.voineskos@medportal.ca</a>
- 7. Manraj N. Kaur (PT, PhD), Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, United States. <a href="mailto:mkaur17@bwh.harvard.edu">mkaur17@bwh.harvard.edu</a>
- 8. Jørn Bo Thomsen (MD, PhD, Associate Professor), Research Unit of Plastic Surgery, Odense University Hospital, Denmark; Clinical Institute, University of Southern Denmark, Odense Denmark. Joern.bo.thomsen@rsyd.dk
- 9. Ruben N. van Veen (MD), Department of Surgery, OLVG, Amsterdam, The Netherlands. N.vanveen@olvg.nl
- 10. Claus B. Juhl (MD, PhD) University Hospital of Southwest Jutland, Institute for Regional Health Research, University of Southern Denmark and Steno Diabetes Center Odense, Denmark. Claus.Bogh.Juhl@rsyd.dk.
- 11. Alin Andries (MD, PhD), Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Denmark, <a href="mailto:alin.andries2@rsyd.dk">alin.andries2@rsyd.dk</a>.

- 12. René K. Støving (MD, PhD, Professor), Center for Eating Disorders, Odense University Hospital, Denmark. Research Unit for Medical Endocrinology, Odense University Hospital, Denmark; Mental Health Services in the Region of Southern Denmark, Odense. Denmark. <a href="mailto:rene.k.stoving@gmail.com">rene.k.stoving@gmail.com</a>.
- 13. Stefan J. Cano (PhD, CSO), Modus Outcomes Ltd, Cheltenham, United Kingdom, stefan.cano@threadresearch.com
- 14. Anne F. Klassen (DPhil, PhD, Professor), Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. aklass@mcmaster.ca
- 15. Andrea L. Pusic (MD, Professor), Department of Surgery, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, United States. <a href="mailto:apusic@bwh.harvard.edu">apusic@bwh.harvard.edu</a>
- 16. Jens A. Sørensen (MD, PhD, Professor), Research Unit of Plastic Surgery, Odense University Hospital, Denmark; Clinical Institute, University of Southern Denmark, Odense Denmark. Jens.sorensen@rsyd.dk

### **Supplementary**

## Supplementary 1 - Total number of patients in each scale and percentage of patients who achieved the estimated minimal important differences

HRQL	Timepoint	MID	N	N achieved MID	% achieved MID
	1 year	5	400	313	78
Psychological	2 years	5	300	212	71
	3 years	5	76	53	70
	1 year	4	396	285	72
Social	2 years	4	297	204	69
	3 years	4	73	49	67
	1 year	5	364	215	59
Sexual	2 years	5	262	144	55
	3 years	5	55	37	67
	1 year	6	397	358	88
Physical	2 years	5	299	269	85
	3 years	5	75	70	85
	1 year	5	397	350	90
Body Image	2 years	5	298	253	90
	3 years	6	78	66	93

Appearance	Timepoint	MID	N	N achieved MID	% achieved MID
	1 year	4	416	400	96
Body	2 years	4	304	285	94
	3 years	4	88	82	93
	1 year	5	430	350	81
Abdomen	2 years	6	315	241	77
	3 years	6	97	72	74
	1 year	6	421	334	79
Back	2 years	6	309	246	80
	3 years	6	93	72	77
	1 year	6	414	261	63
Buttocks	2 years	6	303	206	68
	3 years	6	87	56	64
	1 year	4	424	244	58

Arms	2 years	4	312	195	63
	3 years	5	94	44	47
	1 year	5	413	200	48
Inner thighs	2 years	6	304	158	52
	3 years	5	84	42	50
	1 year	6	411	302	73
Hips and outer	2 years	6	301	220	73
thighs	3 years	6	83	55	66
	1 year	5	64	45	70
Chest	2 years	5	46	33	72
	3 years	5	13	8	62
	1 year	5	63	33	52
Nipples	2 years	5	44	21	48
	3 years	5	13	7	54
	1 year	5	319	167	52
Stretch marks	2 years	5	223	117	52
	3 years	6	47	29	62
	1 year	6	195	57	29
Skin	2 years	6	147	49	33
	3 years	8	63	19	30

HRQL = Health-related quality of life, MID = minimal important difference, N = number

The supplementary shows the number of patients (N achieved MID) who achieved the estimated minimal important difference (MID) score and the percentage of patients who achieved MID (% achieved MID) in each scale.